JPWO2022047083A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022047083A5 JPWO2022047083A5 JP2023513704A JP2023513704A JPWO2022047083A5 JP WO2022047083 A5 JPWO2022047083 A5 JP WO2022047083A5 JP 2023513704 A JP2023513704 A JP 2023513704A JP 2023513704 A JP2023513704 A JP 2023513704A JP WO2022047083 A5 JPWO2022047083 A5 JP WO2022047083A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- composition
- patient
- combination
- free base
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940126062 Compound A Drugs 0.000 claims 34
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 claims 34
- 239000000203 mixture Substances 0.000 claims 29
- 239000012458 free base Substances 0.000 claims 22
- 230000036470 plasma concentration Effects 0.000 claims 14
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 claims 12
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 claims 12
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 claims 12
- 206010028980 Neoplasm Diseases 0.000 claims 12
- 201000011510 cancer Diseases 0.000 claims 12
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 12
- 238000001990 intravenous administration Methods 0.000 claims 4
- 102000008096 B7-H1 Antigen Human genes 0.000 claims 3
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 3
- 238000002512 chemotherapy Methods 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 238000009097 single-agent therapy Methods 0.000 claims 3
- 229960003852 atezolizumab Drugs 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 210000004369 blood Anatomy 0.000 claims 2
- 229960002621 pembrolizumab Drugs 0.000 claims 2
- 102000006579 Chemokine CXCL10 Human genes 0.000 claims 1
- 108010008978 Chemokine CXCL10 Proteins 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000011002 quantification Methods 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
- 238000002626 targeted therapy Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063070376P | 2020-08-26 | 2020-08-26 | |
| US63/070,376 | 2020-08-26 | ||
| PCT/US2021/047826 WO2022047083A1 (en) | 2020-08-26 | 2021-08-26 | Cancer treatment with tlr agonist |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023539625A JP2023539625A (ja) | 2023-09-15 |
| JP2023539625A5 JP2023539625A5 (https=) | 2024-08-30 |
| JPWO2022047083A5 true JPWO2022047083A5 (https=) | 2024-08-30 |
Family
ID=80355767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023513704A Pending JP2023539625A (ja) | 2020-08-26 | 2021-08-26 | Ｔｌｒアゴニストによるがんの処置 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230346775A1 (https=) |
| EP (1) | EP4203962A4 (https=) |
| JP (1) | JP2023539625A (https=) |
| KR (1) | KR20230057409A (https=) |
| CN (1) | CN116056710A (https=) |
| AU (1) | AU2021332350A1 (https=) |
| CA (1) | CA3192776A1 (https=) |
| WO (1) | WO2022047083A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105899539B (zh) | 2014-01-10 | 2021-11-09 | 博笛生物科技有限公司 | 用于免疫疗法的化合物和组合物 |
| CN115252792A (zh) | 2016-01-07 | 2022-11-01 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-egfr组合 |
| CN118515666A (zh) | 2017-04-27 | 2024-08-20 | 博笛生物科技有限公司 | 2-氨基-喹啉衍生物 |
| IL312120B2 (en) | 2017-06-23 | 2025-06-01 | Birdie Biopharmaceuticals Inc | Pharmaceutical compositions |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105899539B (zh) * | 2014-01-10 | 2021-11-09 | 博笛生物科技有限公司 | 用于免疫疗法的化合物和组合物 |
| EP3166976B2 (en) * | 2014-07-09 | 2026-04-08 | Birdie Biopharmaceuticals Inc. | Anti-pd-l1 combinations for treating tumors |
| IL312120B2 (en) * | 2017-06-23 | 2025-06-01 | Birdie Biopharmaceuticals Inc | Pharmaceutical compositions |
-
2021
- 2021-08-26 CA CA3192776A patent/CA3192776A1/en active Pending
- 2021-08-26 AU AU2021332350A patent/AU2021332350A1/en active Pending
- 2021-08-26 KR KR1020237009853A patent/KR20230057409A/ko active Pending
- 2021-08-26 EP EP21862771.9A patent/EP4203962A4/en active Pending
- 2021-08-26 US US18/023,306 patent/US20230346775A1/en active Pending
- 2021-08-26 CN CN202180053175.7A patent/CN116056710A/zh active Pending
- 2021-08-26 JP JP2023513704A patent/JP2023539625A/ja active Pending
- 2021-08-26 WO PCT/US2021/047826 patent/WO2022047083A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111065411B (zh) | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 | |
| JP6858558B2 (ja) | 新生物疾患の処置、減少、阻害、又は制御において使用するための、免疫調節薬 | |
| IL299376A (en) | Fixed dose combination of pertuzumab plus transtuzumab | |
| JPWO2020249693A5 (https=) | ||
| JP2011511072A (ja) | 結腸直腸癌を治療するためのピコプラチンおよびベバシツマブの使用 | |
| US20220257630A1 (en) | Administration of sting agonist and checkpoint inhibitors | |
| JP2018138551A (ja) | 関節リウマチの治療 | |
| JPWO2020111018A5 (https=) | ||
| TW202033188A (zh) | 藉由免疫檢查點阻礙藥與ｆｏｌｆｉｒｉｎｏｘ療法之併用的癌症治療 | |
| CN105813637A (zh) | 用于治疗慢性疲劳综合征的可溶性鸟苷酸环化酶的激活剂或刺激剂 | |
| US20210267972A1 (en) | Administration of sumo-activating enzyme inhibitor and anti-cd20 antibodies | |
| JP2021152002A5 (https=) | ||
| JPWO2022047083A5 (https=) | ||
| JP2017515843A (ja) | 抗ｅｇｆｒ治療薬の投与量および投与 | |
| ES2935265T3 (es) | Método para tratar acontecimientos adversos inducidos por inhibidores de punto de control | |
| WO2022107027A1 (en) | Administration of sting agonist, checkpoint inhibitors, and radiation | |
| CN112955148B (zh) | Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途 | |
| JPWO2020030977A5 (https=) | ||
| JPWO2022240688A5 (https=) | ||
| US20240207199A1 (en) | Fluorocarbon compositions and methods for enhancing immunotherapy | |
| CN101068564A (zh) | 含有vegf抑制剂与5fu或其中一种衍生物的抗肿瘤组合物 | |
| TW202308641A (zh) | 用於治療癌症之方法及包含cdk抑制劑之給藥方案 | |
| CN118871128A (zh) | 抗tim-3抗体与抗pd-l1抗体的药物组合 | |
| JPWO2020112765A5 (https=) | ||
| Yokoyama et al. | Phase II Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Over 75 Years Old with Alternating Bortezomib/dexamethasone and Lenalidomide/dexamethasone: the MARBLE Trial |